PPARA and metabolic dysfunction-associated steatohepatitis: Lanifibranor, the first pan-PPAR agonist targeting three distinct PPAR isotypes, is currently undergoing Phase III clinical trials involving patients diagnosed with MASH and fibrosis [122].